img

Global Metabolic Disorders Drugs Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Metabolic Disorders Drugs Market Research Report 2024

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
According to Mr Accuracy reports new survey, global Metabolic Disorders Drugs market is projected to reach US$ 160970 million in 2029, increasing from US$ 82150 million in 2022, with the CAGR of 10.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metabolic Disorders Drugs market research.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Metabolic Disorders Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Segment by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other

Segment by Application


Hospital
Retail Pharmacy

Consumption by Region


North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Metabolic Disorders Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Metabolic Disorders Drugs Market Overview
1.1 Product Overview and Scope of Metabolic Disorders Drugs
1.2 Metabolic Disorders Drugs Segment by Type
1.2.1 Global Metabolic Disorders Drugs Market Value Comparison by Type (2024-2034)
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Metabolic Disorders Drugs Segment by Application
1.3.1 Global Metabolic Disorders Drugs Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Metabolic Disorders Drugs Market Size Estimates and Forecasts
1.4.1 Global Metabolic Disorders Drugs Revenue 2018-2029
1.4.2 Global Metabolic Disorders Drugs Sales 2018-2029
1.4.3 Global Metabolic Disorders Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Metabolic Disorders Drugs Market Competition by Manufacturers
2.1 Global Metabolic Disorders Drugs Sales Market Share by Manufacturers (2018-2024)
2.2 Global Metabolic Disorders Drugs Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Metabolic Disorders Drugs Average Price by Manufacturers (2018-2024)
2.4 Global Metabolic Disorders Drugs Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metabolic Disorders Drugs, Product Type & Application
2.7 Metabolic Disorders Drugs Market Competitive Situation and Trends
2.7.1 Metabolic Disorders Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Metabolic Disorders Drugs Players Market Share by Revenue
2.7.3 Global Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Metabolic Disorders Drugs Retrospective Market Scenario by Region
3.1 Global Metabolic Disorders Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Metabolic Disorders Drugs Global Metabolic Disorders Drugs Sales by Region: 2018-2029
3.2.1 Global Metabolic Disorders Drugs Sales by Region: 2018-2024
3.2.2 Global Metabolic Disorders Drugs Sales by Region: 2024-2029
3.3 Global Metabolic Disorders Drugs Global Metabolic Disorders Drugs Revenue by Region: 2018-2029
3.3.1 Global Metabolic Disorders Drugs Revenue by Region: 2018-2024
3.3.2 Global Metabolic Disorders Drugs Revenue by Region: 2024-2029
3.4 North America Metabolic Disorders Drugs Market Facts & Figures by Country
3.4.1 North America Metabolic Disorders Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Metabolic Disorders Drugs Sales by Country (2018-2029)
3.4.3 North America Metabolic Disorders Drugs Revenue by Country (2018-2029)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Metabolic Disorders Drugs Market Facts & Figures by Country
3.5.1 Europe Metabolic Disorders Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Metabolic Disorders Drugs Sales by Country (2018-2029)
3.5.3 Europe Metabolic Disorders Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metabolic Disorders Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Metabolic Disorders Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Metabolic Disorders Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Metabolic Disorders Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Metabolic Disorders Drugs Market Facts & Figures by Country
3.7.1 Latin America Metabolic Disorders Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Metabolic Disorders Drugs Sales by Country (2018-2029)
3.7.3 Latin America Metabolic Disorders Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metabolic Disorders Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Metabolic Disorders Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Metabolic Disorders Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Metabolic Disorders Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Metabolic Disorders Drugs Sales by Type (2018-2029)
4.1.1 Global Metabolic Disorders Drugs Sales by Type (2018-2024)
4.1.2 Global Metabolic Disorders Drugs Sales by Type (2024-2029)
4.1.3 Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
4.2 Global Metabolic Disorders Drugs Revenue by Type (2018-2029)
4.2.1 Global Metabolic Disorders Drugs Revenue by Type (2018-2024)
4.2.2 Global Metabolic Disorders Drugs Revenue by Type (2024-2029)
4.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Metabolic Disorders Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Metabolic Disorders Drugs Sales by Application (2018-2029)
5.1.1 Global Metabolic Disorders Drugs Sales by Application (2018-2024)
5.1.2 Global Metabolic Disorders Drugs Sales by Application (2024-2029)
5.1.3 Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
5.2 Global Metabolic Disorders Drugs Revenue by Application (2018-2029)
5.2.1 Global Metabolic Disorders Drugs Revenue by Application (2018-2024)
5.2.2 Global Metabolic Disorders Drugs Revenue by Application (2024-2029)
5.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Metabolic Disorders Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Merck Metabolic Disorders Drugs Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Novartis Metabolic Disorders Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Takeda Pharmaceutical
6.3.1 Takeda Pharmaceutical Corporation Information
6.3.2 Takeda Pharmaceutical Description and Business Overview
6.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Product Portfolio
6.3.5 Takeda Pharmaceutical Recent Developments/Updates
6.4 Astra Zeneca
6.4.1 Astra Zeneca Corporation Information
6.4.2 Astra Zeneca Description and Business Overview
6.4.3 Astra Zeneca Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Astra Zeneca Metabolic Disorders Drugs Product Portfolio
6.4.5 Astra Zeneca Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 KOWA
6.6.1 KOWA Corporation Information
6.6.2 KOWA Description and Business Overview
6.6.3 KOWA Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.6.4 KOWA Metabolic Disorders Drugs Product Portfolio
6.6.5 KOWA Recent Developments/Updates
6.7 Kythera
6.6.1 Kythera Corporation Information
6.6.2 Kythera Description and Business Overview
6.6.3 Kythera Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Kythera Metabolic Disorders Drugs Product Portfolio
6.7.5 Kythera Recent Developments/Updates
6.8 Fuji yakuhin
6.8.1 Fuji yakuhin Corporation Information
6.8.2 Fuji yakuhin Description and Business Overview
6.8.3 Fuji yakuhin Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Fuji yakuhin Metabolic Disorders Drugs Product Portfolio
6.8.5 Fuji yakuhin Recent Developments/Updates
6.9 LG Life Science
6.9.1 LG Life Science Corporation Information
6.9.2 LG Life Science Description and Business Overview
6.9.3 LG Life Science Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.9.4 LG Life Science Metabolic Disorders Drugs Product Portfolio
6.9.5 LG Life Science Recent Developments/Updates
6.10 Metsubishi Tanabe Pharma
6.10.1 Metsubishi Tanabe Pharma Corporation Information
6.10.2 Metsubishi Tanabe Pharma Description and Business Overview
6.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Portfolio
6.10.5 Metsubishi Tanabe Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metabolic Disorders Drugs Industry Chain Analysis
7.2 Metabolic Disorders Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metabolic Disorders Drugs Production Mode & Process
7.4 Metabolic Disorders Drugs Sales and Marketing
7.4.1 Metabolic Disorders Drugs Sales Channels
7.4.2 Metabolic Disorders Drugs Distributors
7.5 Metabolic Disorders Drugs Customers
8 Metabolic Disorders Drugs Market Dynamics
8.1 Metabolic Disorders Drugs Industry Trends
8.2 Metabolic Disorders Drugs Market Drivers
8.3 Metabolic Disorders Drugs Market Challenges
8.4 Metabolic Disorders Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Metabolic Disorders Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Metabolic Disorders Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Metabolic Disorders Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Metabolic Disorders Drugs Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Metabolic Disorders Drugs Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Metabolic Disorders Drugs Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Metabolic Disorders Drugs Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Metabolic Disorders Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Metabolic Disorders Drugs, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Metabolic Disorders Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Metabolic Disorders Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Metabolic Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Metabolic Disorders Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Metabolic Disorders Drugs Sales by Region (2018-2024) & (K Units)
Table 18. Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2024)
Table 19. Global Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global Metabolic Disorders Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Metabolic Disorders Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2024)
Table 23. Global Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Metabolic Disorders Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Metabolic Disorders Drugs Sales by Country (2018-2024) & (K Units)
Table 27. North America Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America Metabolic Disorders Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Metabolic Disorders Drugs Sales by Country (2018-2024) & (K Units)
Table 32. Europe Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe Metabolic Disorders Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Metabolic Disorders Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Metabolic Disorders Drugs Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Metabolic Disorders Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Metabolic Disorders Drugs Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Metabolic Disorders Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Metabolic Disorders Drugs Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Metabolic Disorders Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Metabolic Disorders Drugs Sales (K Units) by Type (2018-2024)
Table 51. Global Metabolic Disorders Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2024)
Table 53. Global Metabolic Disorders Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Metabolic Disorders Drugs Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Metabolic Disorders Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2024)
Table 57. Global Metabolic Disorders Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Metabolic Disorders Drugs Price (USD/Unit) by Type (2018-2024)
Table 59. Global Metabolic Disorders Drugs Price (USD/Unit) by Type (2024-2029)
Table 60. Global Metabolic Disorders Drugs Sales (K Units) by Application (2018-2024)
Table 61. Global Metabolic Disorders Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2024)
Table 63. Global Metabolic Disorders Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Metabolic Disorders Drugs Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Metabolic Disorders Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2024)
Table 67. Global Metabolic Disorders Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Metabolic Disorders Drugs Price (USD/Unit) by Application (2018-2024)
Table 69. Global Metabolic Disorders Drugs Price (USD/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. Merck Metabolic Disorders Drugs Product
Table 74. Merck Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Novartis Metabolic Disorders Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Takeda Pharmaceutical Corporation Information
Table 81. Takeda Pharmaceutical Description and Business Overview
Table 82. Takeda Pharmaceutical Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. Takeda Pharmaceutical Metabolic Disorders Drugs Product
Table 84. Takeda Pharmaceutical Recent Developments/Updates
Table 85. Astra Zeneca Corporation Information
Table 86. Astra Zeneca Description and Business Overview
Table 87. Astra Zeneca Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 88. Astra Zeneca Metabolic Disorders Drugs Product
Table 89. Astra Zeneca Recent Developments/Updates
Table 90. Boehringer Ingelheim Corporation Information
Table 91. Boehringer Ingelheim Description and Business Overview
Table 92. Boehringer Ingelheim Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 93. Boehringer Ingelheim Metabolic Disorders Drugs Product
Table 94. Boehringer Ingelheim Recent Developments/Updates
Table 95. KOWA Corporation Information
Table 96. KOWA Description and Business Overview
Table 97. KOWA Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 98. KOWA Metabolic Disorders Drugs Product
Table 99. KOWA Recent Developments/Updates
Table 100. Kythera Corporation Information
Table 101. Kythera Description and Business Overview
Table 102. Kythera Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 103. Kythera Metabolic Disorders Drugs Product
Table 104. Kythera Recent Developments/Updates
Table 105. Fuji yakuhin Corporation Information
Table 106. Fuji yakuhin Description and Business Overview
Table 107. Fuji yakuhin Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 108. Fuji yakuhin Metabolic Disorders Drugs Product
Table 109. Fuji yakuhin Recent Developments/Updates
Table 110. LG Life Science Corporation Information
Table 111. LG Life Science Description and Business Overview
Table 112. LG Life Science Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. LG Life Science Metabolic Disorders Drugs Product
Table 114. LG Life Science Recent Developments/Updates
Table 115. Metsubishi Tanabe Pharma Corporation Information
Table 116. Metsubishi Tanabe Pharma Description and Business Overview
Table 117. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product
Table 119. Metsubishi Tanabe Pharma Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Metabolic Disorders Drugs Distributors List
Table 123. Metabolic Disorders Drugs Customers List
Table 124. Metabolic Disorders Drugs Market Trends
Table 125. Metabolic Disorders Drugs Market Drivers
Table 126. Metabolic Disorders Drugs Market Challenges
Table 127. Metabolic Disorders Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Metabolic Disorders Drugs
Figure 2. Global Metabolic Disorders Drugs Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Metabolic Disorders Drugs Market Share by Type in 2022 & 2029
Figure 4. Glycogen Metabolism Disease Drug Product Picture
Figure 5. Lipid Metabolism Disease Drug Product Picture
Figure 6. Amino Acid Metabolism Drug Product Picture
Figure 7. Other Product Picture
Figure 8. Global Metabolic Disorders Drugs Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Metabolic Disorders Drugs Market Share by Application in 2022 & 2029
Figure 10. Hospital
Figure 11. Retail Pharmacy
Figure 12. Global Metabolic Disorders Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Metabolic Disorders Drugs Market Size (2018-2029) & (US$ Million)
Figure 14. Global Metabolic Disorders Drugs Sales (2018-2029) & (K Units)
Figure 15. Global Metabolic Disorders Drugs Average Price (USD/Unit) & (2018-2029)
Figure 16. Metabolic Disorders Drugs Report Years Considered
Figure 17. Metabolic Disorders Drugs Sales Share by Manufacturers in 2022
Figure 18. Global Metabolic Disorders Drugs Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Metabolic Disorders Drugs Players: Market Share by Revenue in 2022
Figure 20. Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Metabolic Disorders Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Metabolic Disorders Drugs Sales Market Share by Country (2018-2029)
Figure 23. North America Metabolic Disorders Drugs Revenue Market Share by Country (2018-2029)
Figure 24. the United States Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Metabolic Disorders Drugs Sales Market Share by Country (2018-2029)
Figure 27. Europe Metabolic Disorders Drugs Revenue Market Share by Country (2018-2029)
Figure 28. Germany Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. UK Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Metabolic Disorders Drugs Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Metabolic Disorders Drugs Revenue Market Share by Region (2018-2029)
Figure 35. China Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Metabolic Disorders Drugs Sales Market Share by Country (2018-2029)
Figure 45. Latin America Metabolic Disorders Drugs Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Metabolic Disorders Drugs Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Metabolic Disorders Drugs Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Metabolic Disorders Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Metabolic Disorders Drugs by Type (2018-2029)
Figure 55. Global Revenue Market Share of Metabolic Disorders Drugs by Type (2018-2029)
Figure 56. Global Metabolic Disorders Drugs Price (USD/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Metabolic Disorders Drugs by Application (2018-2029)
Figure 58. Global Revenue Market Share of Metabolic Disorders Drugs by Application (2018-2029)
Figure 59. Global Metabolic Disorders Drugs Price (USD/Unit) by Application (2018-2029)
Figure 60. Metabolic Disorders Drugs Value Chain
Figure 61. Metabolic Disorders Drugs Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed